BME
In January 2018, Paradigm Biopharmaceuticals Ltd announced that it had been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS), and throughout 2018 has validated the patent in European member states. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in Australia, the United States, Japan, China, Canada, Taiwan, Singapore and other countries across the Asia-Pacific.
So this is Bullshit then
- Forums
- ASX - By Stock
- PAR
- Paradigm patent rejection
Paradigm patent rejection, page-27
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M |
Open | High | Low | Value | Volume |
27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5500 | 26.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 36162 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 61837 | 0.255 |
2 | 25200 | 0.250 |
1 | 15000 | 0.245 |
3 | 85000 | 0.240 |
1 | 8510 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.265 | 583 | 1 |
0.270 | 25000 | 1 |
0.275 | 3350 | 1 |
0.285 | 46000 | 1 |
0.290 | 44274 | 3 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |